David Hanna is a senior counsel in the Life Sciences Group in the Litigation Department, where he focuses on biologic drug patent and Hatch-Waxman patent litigation. David’s biologics drug patent litigation experience includes litigating matters relating to Stelara® (ustekinumab), Avastin® (bevacizumab), and Herceptin® (trastuzumab).
David has represented both patentees and generic filers in Hatch-Waxman litigation. He has litigated matters relating to Imbruvica® (ibrutinib), Xarelto® (rivaroxaban), Suboxone® (buprenorphine naloxone), Pradaxa® (dabigatran etexilate), Ultiva® (remifentanil hydrochloride), Daytrana® (methylphenidate), Dymista® (azelastine HCl/fluticasone propionate), Epaned® (enalapril maleate), and Brisdelle® (paroxetine).
David has also represented a major pharmaceutical company in product liability matters relating to Viread®, Truvada®, Atripla®, and other antiviral medications containing tenofovir disoproxil fumarate (“TDF”).
In the top law firm directory The Legal 500 US, a client recommended David, noting his client service for being “super responsive and very detail oriented.”
Education
-
University of Minnesota Law School, J.D.
Lead Article Editor, Minnesota Journal of Law, Science & Technology
University of Minnesota, M.S., Chemistry
University of Pittsburgh, B.S., Chemistry, summa cum laude
Admissions & Qualifications
- U.S. Patent and Trademark Office
- Illinois
- California
Memberships
Member at Large, SCALACS Executive Committee
Board Member, Echo Theater Company
Awards & Recognition
Southern California Super Lawyers Rising Star 2020-2023
The Legal 500 United States: Healthcare: Life Sciences 2020
Best Lawyers in America: Ones to Watch 2021-2023